Inhibikase Therapeutics, Inc. (IKT)
2.43
0.00 (0.00%)
USD |
NASDAQ |
Sep 09, 11:42
Inhibikase Therapeutics Price to Book Value : 2.092 for Sept. 9, 2026
Price to Book Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Price to Book Value Data
| Date | Value |
|---|---|
| September 08, 2026 | 2.092 |
| September 04, 2026 | 2.153 |
| September 03, 2026 | 2.17 |
| September 02, 2026 | 2.153 |
| September 01, 2026 | 2.049 |
| August 31, 2026 | 1.989 |
| August 28, 2026 | 2.075 |
| August 27, 2026 | 2.127 |
| August 26, 2026 | 2.144 |
| August 25, 2026 | 2.153 |
| August 24, 2026 | 2.153 |
| August 21, 2026 | 2.058 |
| August 20, 2026 | 2.024 |
| August 19, 2026 | 2.110 |
| August 18, 2026 | 2.067 |
| August 17, 2026 | 2.058 |
| August 14, 2026 | 2.075 |
| August 13, 2026 | 2.075 |
| August 12, 2026 | 2.067 |
| August 11, 2026 | 2.110 |
| August 10, 2026 | 2.118 |
| August 07, 2026 | 2.127 |
| August 06, 2026 | 2.075 |
| August 05, 2026 | 2.067 |
| August 04, 2026 | 2.101 |
| Date | Value |
|---|---|
| August 03, 2026 | 1.903 |
| July 31, 2026 | 1.877 |
| July 30, 2026 | 1.963 |
| July 29, 2026 | 1.903 |
| July 28, 2026 | 1.989 |
| July 27, 2026 | 2.024 |
| July 24, 2026 | 2.006 |
| July 23, 2026 | 2.006 |
| July 22, 2026 | 1.869 |
| July 21, 2026 | 1.920 |
| July 20, 2026 | 1.920 |
| July 17, 2026 | 1.817 |
| July 16, 2026 | 1.731 |
| July 15, 2026 | 1.774 |
| July 14, 2026 | 1.774 |
| July 13, 2026 | 1.688 |
| July 10, 2026 | 1.757 |
| July 09, 2026 | 1.757 |
| July 08, 2026 | 1.782 |
| July 07, 2026 | 1.765 |
| July 06, 2026 | 1.705 |
| July 02, 2026 | 1.714 |
| July 01, 2026 | 1.671 |
| June 30, 2026 | 1.748 |
| June 29, 2026 | 1.520 |
Price to Book Ratio Definition
Price to book value is a valuation ratio that is measured by stock price / book value per share. The book value is essentially the tangible accounting value of a firm compared to the market value that is shown.
Price to Book Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Price to Book Value Benchmarks
| ACADIA Pharmaceuticals, Inc. | 3.674 |
| Alnylam Pharmaceuticals, Inc. | 25.26 |
| Anika Therapeutics, Inc. | 2.043 |
| Savara, Inc. | 7.714 |
| Vericel Corp. | 5.381 |
Price to Book Value Related Metrics
| Price | 2.43 |
| Earnings Yield | -17.96% |
| Market Cap | 320.84M |